Physician profile
Daniel Berger
NPI 1073950390
$80,911.75
in general payments reported to CMS, 2019-2025
29 companies · $959 in 2025
The $959 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $504 · 2020: $23K · 2021: $48K · 2022: $7,270 · 2023: $478 · 2024: $515 · 2025: $959.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,457 · Consulting Fee: $380 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,456.64 |
| Consulting Fee | $380.00 |
| Education | $116.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $55,491.47 | 2021-2023 | Pillcam |
| Covidien Lp | $22,086.14 | 2019-2020 | |
| Janssen Biotech, INC. | $638.15 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $530.25 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $396.49 | 2020-2025 | Entyvio |
| Abbvie INC. | $360.15 | 2019-2025 | |
| Erbe USA INC | $192.20 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $188.48 | 2025 | Iqirvo |
| Ardelyx, INC. | $114.42 | 2024-2025 | Ibsrela |
| Pfizer INC. | $95.07 | 2020-2024 | |
| Lilly USA, LLC | $94.40 | 2024 | Omvoh |
| Allergan, INC. | $82.31 | 2019-2020 | |
| Novo Nordisk INC | $76.44 | 2023-2025 | Wegovy |
| Ironwood Pharmaceuticals, INC | $75.31 | 2020 | |
| Endogastric Solutions, INC | $72.14 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $63.22 | 2020 | |
| Theratechnologies INC. | $57.60 | 2023-2024 | Egrifta, Trogarzo |
| Senseonics, Incorporated | $39.00 | 2019 | |
| Braintree Laboratories, INC. | $38.10 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $30.98 | 2025 | Dupixent |
| Blue Earth Diagnostics | $29.32 | 2025 | Posluma |
| Madrigal Pharmaceuticals | $26.80 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $24.02 | 2022 | |
| Intercept Pharmaceuticals, INC. | $21.84 | 2020 | |
| Phathom Pharmaceuticals, INC. | $20.07 | 2024 | Voquezna |
| Ferring Pharmaceuticals INC. | $20.04 | 2020 | |
| Vivus LLC | $19.21 | 2019 | |
| Echosens North America, INC. | $15.05 | 2024 | Fibroscan |
| Laborie Medical Technologies Corp. | $13.08 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Berger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.